Belgian Drugmaker UCB Raises Full-Year Expectations on Strong US Demand

2026-10-22 companies

Brussels, Thursday, 22 October 2026.
UCB raised its 2026 financial guidance on October 22, 2026, projecting earnings growth in the low-to-mid 40% range due to surging U.S. sales for flagship drug Bimzelx.

UCB Raises 2026 Financial Guidance

Belgian biopharmaceutical group UCB announced an upward revision to its full-year 2026 financial guidance on October 22, 2026, citing sustained commercial momentum across its product portfolio [1]. The company now anticipates revenue growth in the low twenties percentage range on a constant exchange rate basis, an increase from the previous forecast of low- to mid-teens growth [1][2]. Adjusted EBITDA growth is now projected in the low- to mid-forties percentage range, compared to the prior guidance of mid-teens to low-twenties [1][3]. This strategic upgrade reflects accelerated top-line revenue growth and expanding operating margins driven by core therapeutic pipelines in key global markets [2].

Market Reaction and Stock Performance

Following the announcement, UCB stock experienced significant gains, trading at €243.30 at Lang & Schwarz on October 22, 2026 [4]. This price point represented a 14.23% increase over the October 21, 2026, Xetra closing price of €213.00 [4]. Analysts responded positively to the news, with KBC Securities reiterating a buy recommendation and a price target of €270 [2]. ING also maintained a buy recommendation with a €304 target, noting that consensus forecasts for adjusted EBITDA should rise by at least 17% [2]. The market reaction underscores investor confidence in the company’s operational resilience and commercial strength [2].

Flagship Drug Performance

The upward adjustment is driven primarily by robust demand for two leading flagship treatments, Bimzelx and Cimzia [1]. Bimzelx sales performance is a primary driver for the guidance increase, with accelerating US demand and market share gains contributing to revenue projections [2][3]. Cimzia is also contributing through volume growth and better pricing, despite contraction in the anti-TNF sector [1][3]. The reported financial guidance excludes potential proceeds from the sale of a Priority Review Voucher, which would provide an additional low- to mid-single-digit percentage points uplift to both revenue and adjusted EBITDA [1][6].

Analyst Projections and Future Outlook

Jefferies analysis suggests the new guidance implies revenue of €9.1bn–€9.3bn and adjusted EBITDA of €3.5bn–€3.6bn, exceeding Visible Alpha consensus expectations [2][3]. UCB is scheduled to publish Full Year 2026 results and 2027 financial guidance on February 25, 2027 [1][4]. The company cautions that financial performance is subject to external variables, including pricing pressure and legislative impacts on biopharmaceutical reimbursement [1]. Management remains confident in the ability to translate innovation into sustainable growth while continuing to invest in future pipelines [1][6].

Sources

Biopharmaceuticals Financial Guidance